Signal Advisors Wealth LLC Sells 2,744 Shares of United Therapeutics Corporation $UTHR

Signal Advisors Wealth LLC lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 51.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,595 shares of the biotechnology company’s stock after selling 2,744 shares during the period. Signal Advisors Wealth LLC’s holdings in United Therapeutics were worth $1,088,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Chung Wu Investment Group LLC purchased a new stake in shares of United Therapeutics during the 2nd quarter worth $29,000. SVB Wealth LLC bought a new position in United Therapeutics in the first quarter worth about $32,000. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $450.24, for a total transaction of $10,130,400.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 625,164 shares of company stock valued at $284,916,107. Corporate insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on UTHR. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. UBS Group boosted their target price on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $505.00.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $517.13 on Friday. The company has a market capitalization of $22.27 billion, a PE ratio of 19.60, a price-to-earnings-growth ratio of 5.13 and a beta of 0.86. The company’s fifty day moving average price is $463.63 and its 200 day moving average price is $380.95. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $518.61.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. During the same quarter in the prior year, the firm posted $6.39 earnings per share. The company’s revenue was up 6.8% compared to the same quarter last year. On average, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.